MedPath

Phase I study of hepatic arterial infusion chemotherapy with Miriplatin and 5-fluorouracil(MiF) for advanced HCC

Phase 1
Conditions
Hepatocellular carcinoma
Registration Number
JPRN-UMIN000003302
Lead Sponsor
Division of Gastroenterology,Kurume University School of Medicine
Brief Summary

CR/PR/SD/PD:1/5/3/1 OS 6 months:90% , 12 manths:48% MST:297 days Safety: no ploblem

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
10
Inclusion Criteria

Not provided

Exclusion Criteria

1.Previous chemothrapy or TAE 2.Previous operation or RFA or PEIT within 6 months. 3.Extrahepatic metastasis or lymph nodes metastasis. 4.Concurrent infections(without hepatitis virus) 5.Active double cancers 6.Medical history of severe hypersensitivity. 7.Pregnant,lacting women or women with suspected pregnancy. 8.Inappropriate patients for this study judged by physicians.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
complication
Secondary Outcome Measures
NameTimeMethod
response evaluation overall survival
Âİ Copyright 2025. All Rights Reserved by MedPath